Nvidia Denies Upfront Payment Requirement for H200 AI Chips Amid China Export Scrutiny 
BlueScope Steel Announces A$1 Special Dividend After Asset Sales 
Boeing Reaches Tentative Settlement With Canadian Victim’s Family in 737 MAX Crash Lawsuits 
Rio Tinto and BHP Agree to Explore Major Iron Ore Collaboration in Pilbara 
Microsoft Strikes Landmark Soil Carbon Credit Deal With Indigo Carbon to Boost Carbon-Negative Goal 
Netflix Plans All-Cash Bid for Warner Bros Discovery Studios Amid Intense Hollywood Takeover Battle 
U.S. Lawmakers Raise Alarm Over Trump Approval of Nvidia AI Chip Sales to China 
Tesla, EEOC Move Toward Mediation in Racial Harassment Lawsuit 
Trump Administration Approves Nvidia H200 AI Chip Sales to China Under New Export Rules 
U.S. Government Invests $1 Billion in L3Harris Rocket Motor Business to Secure Missile Supply Chain 
Merck Raises Growth Outlook, Targets $70 Billion Revenue From New Drugs by Mid-2030s 
AbbVie Commits $100 Billion to U.S. Investment in Drug Pricing Deal With Trump Administration 
Amazon Reviews Supplier Costs as U.S.–China Tariffs Ease 
xAI Restricts Grok Image Editing After Sexualized AI Images Trigger Global Scrutiny 
SK Hynix to Invest $13 Billion in Advanced Chip Packaging Plant as AI Memory Demand Surges 
Alphabet Stock Poised for Growth as Bank of America Sees Strong AI Momentum Into 2026 
IRVINE, Calif., April 05, 2017 -- Khang & Khang LLP (the “Firm”) announces a class action lawsuit against Kitov Pharmaceuticals Holdings Ltd (“Kitov” or the “Company”) (Nasdaq:KTOV). Investors who purchased Kitov American Depositary Receipts (“ADRs”) pursuant to the Company’s initial public offering on or about November 20, 2015 (the “IPO”) and/or between November 20, 2015 and February 3, 2017 inclusive (the “Class Period”), are encouraged to contact the Firm before the April 10, 2017 lead plaintiff motion deadline.
If you purchased Kitov shares during the IPO or Class Period, please contact Joon M. Khang, Esquire, of Khang & Khang, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949) 419-3834, or by e-mail at [email protected].
There has been no class certification in this case. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member.
According to the Complaint, Kitov made false and/or misleading statements and/or failed to disclose that the Company and its CEO Isaac Israel, published misleading information concerning the conduct of the Company’s clinical trials for its lead drug candidate, KIT-302, and consequently, Kitov’s public statements were materially false and misleading at all relevant times. On February 6, 2017, Calcalist, an Israeli publication, reported that Isaac Israel was detained and questioned by the Israeli Securities Authority for allegedly publishing misleading information about the Company’s recent clinical trial.
If you wish to learn more about this lawsuit, or if you have questions concerning this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone: (949) 419-3834, or via e-mail at [email protected].
This press release may constitute Attorney Advertising in some jurisdictions.
Contacts Joon M. Khang, Esq. Telephone: 949-419-3834 Facsimile: 949-225-4474 [email protected]
